Login / Signup

Impact of insurance status on overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Ravi J ChokshiJin K KimJimmy PatelJoseph B OliverOmar Mahmoud
Published in: Pleura and peritoneum (2020)
In this small, exploratory study, there was no statistical difference in OS between insured and underinsured patients after CRS-HIPEC. However, long-term survivors were observed only in the insured group.
Keyphrases